European Union - English - EMA (European Medicines Agency)

intervet international b.v. - porcine circovirus type 2 (pcv2) orf2 subunit antigen, mycoplasma hyopneumoniae j strain inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs (for fattening) - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (pcv2) infection, and severity of lung lesions caused by mycoplasma hyopneumoniae infection. to reduce the loss of daily weight gain during the finishing period in face of infections with mycoplasma hyopneumoniae and/or pcv2 (as observed in field studies)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - porcine circovirus type 2 orf2 subunit antigen; mycoplasma hyopneumoniae - inactivated antigen - vaccine or antisera - porcine circovirus type 2 orf2 subunit antigen vaccine-viral active 1414.0 au/ml; mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 2.69 rp - immunotherapy

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - mycoplasma hyopneumoniae, porcine circovirus-2 - emulsion for injection - inactivated viral and bacterial vaccine - pigs

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - mycoplasma hyopneumoniae; porcine circovirus type 2 orf-2 protein - mycoplasma hyopneumoniae 0 vaccine; porcine circovirus type 2 orf-2 protein 0 vaccine - vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - porcine parvo virus - inactivated; thiomersal - misc. vaccines or anti sera - porcine parvo virus - inactivated vaccine-viral active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - parvovirus

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - porcine parvovirus (inactivated) - porcine parvovirus (inactivated) 0 vaccine - vaccine

Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - porcine epidemic diarrhea virus (pedv) vaccine (vet.) - solution for injection (im) - formulation: each dose contains: porcine epidemic diarrhea replicon particle............>5 x 10rp rp-relative potency

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - porcine circovirus type 2 orf2 subunit antigen - unknown - porcine circovirus type 2 orf2 subunit antigen vaccine-viral active 0.0 - active constituent

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.

European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.